Patients Is women’s health reaching an inflection point? A half-day symposium – titled Women’s Health: From Intractable to Investable – was held in London on 11th June, organised by Weatherden.
R&D Regulatory setback or scientific signal? The case for human-... Exploring a systemic challenge in translating biological promise into reliable human efficacy and safety.
R&D From data to impact: How real-world evidence will transform ... Real-world evidence (RWE) has moved from the periphery to the centre of how healthcare decisions are made.
R&D The irony of data in precision medicine: Igniting progress w... As I regularly engage with pharma executives and biotech founders, a common theme inevitably arises: why is precision medicine taking so long to become a reality, and is technology to blame
Digital Tech & Trials: Can AI save us from drowning in data? Data – it’s everywhere! Especially in clinical trials, where an average trial of about 2,000 patients can expect to produce 3,000,000 points of data.
News Isomorphic Labs raises $5bn in massive third round In yet another sign of the appetite for AI companies among investors, Isomorphic Labs has raised a whopping $5bn in a Series C financing.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.